Erythropoietin is effective in improving the anemia induced by imatinib mesylate therapy in patients with chronic myeloid leukemia in chronic phase

BACKGROUND Myelosuppression occurs in up to 50% of patients with chronic myeloid leukemia (CML) who are treated with imatinib and ≥ Grade 3 myelosuppression is reported in approximately 10% of patients. METHODS The authors investigated the prognostic significance of anemia occurring during therapy w...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Cancer 2004-06, Vol.100 (11), p.2396-2402
Hauptverfasser:	Cortes, Jorge, O'Brien, Susan, Quintas, Alfonso, Giles, Francis, Shan, Jianquin, Rios, Mary Beth, Talpaz, Moshe, Kantarjian, Hagop
Format:	Artikel
Sprache:	eng
Schlagworte:	anemia Anemia - chemically induced Anemia - drug therapy Anemias. Hemoglobinopathies Antineoplastic Agents - adverse effects Benzamides Biological and medical sciences chronic myeloid leukemia Diseases of red blood cells erythropoietin Erythropoietin - therapeutic use Female Hematologic and hematopoietic diseases Humans imatinib Imatinib Mesylate Injections, Subcutaneous Interferon-alpha - adverse effects Leukemia, Myelogenous, Chronic, BCR-ABL Positive - drug therapy Leukemia, Myelogenous, Chronic, BCR-ABL Positive - pathology Leukemia, Myeloid, Chronic-Phase - drug therapy Leukemia, Myeloid, Chronic-Phase - pathology Leukemias. Malignant lymphomas. Malignant reticulosis. Myelofibrosis Medical sciences Middle Aged Piperazines - adverse effects Prognosis Protein-Tyrosine Kinases - antagonists & inhibitors Pyrimidines - adverse effects Recombinant Proteins Survival Rate Treatment Outcome
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!